{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:10:11Z","timestamp":1789513811270,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00262-019-02389-7","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T14:02:50Z","timestamp":1567864970000},"page":"1561-1572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients"],"prefix":"10.1007","volume":"68","author":[{"given":"Benoit","family":"Milcent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Josseaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Riller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Giglioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Rabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Deligne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Latouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Hamieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Couture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Toutirais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chun","family":"Lone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Jeger-Madiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Graff-Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Toubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Teillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-2886","authenticated-orcid":false,"given":"Sophie","family":"Sib\u00e9ril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,7]]},"reference":[{"key":"2389_CR1","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","volume":"8","author":"MJE Marshall","year":"2017","unstructured":"Marshall MJE, Stopforth RJ, Cragg MS (2017) Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol 8:1245","journal-title":"Front Immunol"},{"key":"2389_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","volume":"47","author":"SA Beers","year":"2010","unstructured":"Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ (2010) CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 47:107\u2013114","journal-title":"Semin Hematol"},{"key":"2389_CR3","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","volume":"125","author":"P Stashenko","year":"1980","unstructured":"Stashenko P, Nadler LM, Hardy R, Schlossman SF (1980) Characterization of a human B lymphocyte-specific antigen. J Immunol 125:1678\u20131685","journal-title":"J Immunol"},{"key":"2389_CR4","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1073\/pnas.78.6.3848","volume":"78","author":"P Stashenko","year":"1981","unstructured":"Stashenko P, Nadler LM, Hardy R, Schlossman SF (1981) Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci USA 78:3848\u20133852","journal-title":"Proc Natl Acad Sci USA"},{"key":"2389_CR5","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.4049\/jimmunol.126.5.1941","volume":"126","author":"LM Nadler","year":"1981","unstructured":"Nadler LM, Stashenko P, Hardy R, van Agthoven A, Terhorst C, Schlossman SF (1981) Characterization of a human B cell-specific antigen (B2) distinct from B1. J Immunol 126:1941\u20131947","journal-title":"J Immunol"},{"key":"2389_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","volume":"15","author":"TF Tedder","year":"1994","unstructured":"Tedder TF, Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15:450\u2013454","journal-title":"Immunol Today"},{"key":"2389_CR7","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.4049\/jimmunol.151.9.4494","volume":"151","author":"JP Deans","year":"1993","unstructured":"Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A, Clark EA, Ledbetter JA (1993) Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 151:4494\u20134504","journal-title":"J Immunol"},{"key":"2389_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1074\/jbc.273.1.344","volume":"273","author":"JP Deans","year":"1998","unstructured":"Deans JP, Robbins SM, Polyak MJ, Savage JA (1998) Rapid redistribution of CD20 to a low-density detergent-insoluble membrane compartment. J Biol Chem 273:344\u2013348","journal-title":"J Biol Chem"},{"key":"2389_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1083\/jcb.121.5.1121","volume":"121","author":"JK Bubien","year":"1993","unstructured":"Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2\u2009+\u2009conductance found constitutively in B lymphocytes. J Cell Biol 121:1121\u20131132","journal-title":"J Cell Biol"},{"key":"2389_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Sch\u00e4fer W, Georges G, Schwaiger M, M\u00f6ssner E, Hopfner KP, Uma\u00f1a P, Niederfellner G (2013) Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 5:22\u201333","journal-title":"MAbs"},{"key":"2389_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","volume":"177","author":"JL Teeling","year":"2006","unstructured":"Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ, van de Winkel JG (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177:362\u2013371","journal-title":"J Immunol"},{"key":"2389_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1182\/blood-2009-10-248609","volume":"116","author":"R Ab\u00e8s","year":"2010","unstructured":"Ab\u00e8s R, G\u00e9liz\u00e9 E, Fridman WH, Teillaud JL (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116:926\u2013934","journal-title":"Blood"},{"key":"2389_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/leu.2014.275","volume":"29","author":"C Deligne","year":"2015","unstructured":"Deligne C, Metidji A, Fridman WH, Teillaud JL (2015) Anti-CD20 therapy induces a memory Th1 response through the IFN-\u03b3\/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia 29:947\u2013957","journal-title":"Leukemia"},{"key":"2389_CR14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cell.2015.04.016","volume":"161","author":"DJ DiLillo","year":"2015","unstructured":"DiLillo DJ, Ravetch JV (2015) Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 161:1035\u20131045","journal-title":"Cell"},{"key":"2389_CR15","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1074\/mcp.M112.024810","volume":"12","author":"C Hassan","year":"2013","unstructured":"Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, Leunissen JA, Heemskerk MH, Falkenburg JH, van Veelen PA (2013) The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics 12:1829\u20131843","journal-title":"Mol Cell Proteomics"},{"key":"2389_CR16","doi-asserted-by":"publisher","first-page":"E166","DOI":"10.1073\/pnas.1416389112","volume":"112","author":"DJ Kowalewski","year":"2015","unstructured":"Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS (2015) HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci USA 112:E166\u2013E175","journal-title":"Proc Natl Acad Sci USA"},{"key":"2389_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/1078-0432.CCR-03-0075","volume":"10","author":"M Grube","year":"2004","unstructured":"Grube M, Rezvani K, Wiestner A, Fujiwara H, Sconocchia G, Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA (2004) Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies. Clin Cancer Res 10:1047\u20131056","journal-title":"Clin Cancer Res"},{"key":"2389_CR18","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1158\/1078-0432.CCR-04-1612","volume":"11","author":"J Bae","year":"2005","unstructured":"Bae J, Martinson JA, Klingemann HG (2005) Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Clin Cancer Res 11:1629\u20131638","journal-title":"Clin Cancer Res"},{"key":"2389_CR19","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1002\/ijc.26209","volume":"130","author":"IW Abrahamsen","year":"2012","unstructured":"Abrahamsen IW, Kjellevoll S, Greve-Isdahl M, Mensali N, W\u00e4lchli S, Kumari S, Loland BF, Egeland T, Kolstad A, Olweus J (2012) T cells raised against allogeneic HLA-A2\/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells. Int J Cancer 130:1821\u20131832","journal-title":"Int J Cancer"},{"issue":"5","key":"2389_CR20","doi-asserted-by":"publisher","first-page":"e1138199","DOI":"10.1080\/2162402X.2016.1138199","volume":"18","author":"N Mensali","year":"2016","unstructured":"Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, Fallang LE, Kolstad A, Uckert W, Malmberg KJ, W\u00e4lchli S, Olweus J (2016) Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA. Oncoimmunology 18(5):e1138199","journal-title":"Oncoimmunology"},{"key":"2389_CR21","doi-asserted-by":"crossref","first-page":"77021","DOI":"10.18632\/oncotarget.12778","volume":"7","author":"L Jahn","year":"2016","unstructured":"Jahn L, van der Steen DM, Hagedoorn RS, Hombrink P, Kester MG, Schoonakker MP, de Ridder D, van Veelen PA, Falkenburg JH, Heemskerk MH (2016) Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies. Oncotarget 7:77021\u201377037","journal-title":"Oncotarget"},{"key":"2389_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1073\/pnas.1306549111","volume":"111","author":"S Kumari","year":"2014","unstructured":"Kumari S, W\u00e4lchli S, Fallang LE, Yang W, Lund-Johansen F, Schumacher TN, Olweus J (2014) Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc Natl Acad Sci USA 111:403\u2013408","journal-title":"Proc Natl Acad Sci USA"},{"key":"2389_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ijc.29366","volume":"137","author":"C Vauchy","year":"2015","unstructured":"Vauchy C, Gamonet C, Ferrand C, Daguindau E, Galaine J, Beziaud L, Chauchet A, Henry Dunand CJ, Deschamps M, Rohrlich PS, Borg C, Adotevi O, Godet Y (2015) CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes. Int J Cancer 137:116\u2013126","journal-title":"Int J Cancer"},{"key":"2389_CR24","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1002\/eji.200425463","volume":"34","author":"A Pajot","year":"2004","unstructured":"Pajot A, Michel ML, Fazilleau N, Pancr\u00e9 V, Auriault C, Ojcius DM, Lemonnier FA, Lone YC (2004) A mouse model of human adaptive immune functions: HLA-A2.1-\/HLA-DR1-transgenic H-2 class I-\/class II-knockout mice. Eur J Immunol 34:3060\u20133069","journal-title":"Eur J Immunol"},{"key":"2389_CR25","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","volume":"171","author":"N Di Gaetano","year":"2003","unstructured":"Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Introna M, Golay J (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581\u20131587","journal-title":"J Immunol"},{"key":"2389_CR26","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/icb.2016.25","volume":"94","author":"A Garnier","year":"2016","unstructured":"Garnier A, Hamieh M, Drouet A, Leprince J, Vivien D, Fr\u00e9bourg T, Le Mauff B, Latouche JB, Toutirais O (2016) Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells. Immunol Cell Biol 94:662\u2013672","journal-title":"Immunol Cell Biol"},{"key":"2389_CR27","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1182\/blood-2011-08-374645","volume":"119","author":"KN Steinitz","year":"2012","unstructured":"Steinitz KN, van Helden PM, Binder B, Wraith DC, Unterthurner S, Hermann C, Schuster M, Ahmad RU, Weiller M, Lubich C, de la Rosa M, Schwarz HP, Reipert BM (2012) CD4\u2009+\u2009T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice. Blood 119:4073\u20134082","journal-title":"Blood"},{"key":"2389_CR28","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/j.1538-7836.2005.01309.x","volume":"3","author":"TD Jones","year":"2005","unstructured":"Jones TD, Phillips WJ, Smith BJ, Bamford CA, Nayee PD, Baglin TP, Gaston JS, Baker MP (2005) Identification and removal of a promiscuous CD4\u2009+\u2009T cell epitope from the C1 domain of factor VIII. J Thromb Haemost 3:991\u20131000","journal-title":"J Thromb Haemost"},{"issue":"M110","key":"2389_CR29","first-page":"002246","volume":"10","author":"SD van Haren","year":"2011","unstructured":"van Haren SD, Herczenik E, ten Brinke A, Mertens K, Voorberg J, Meijer AB (2011) HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII. Mol Cell Proteomics 10(M110):002246","journal-title":"Mol Cell Proteomics"},{"key":"2389_CR30","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/1078-0432.CCR-11-3185","volume":"18","author":"Y Godet","year":"2012","unstructured":"Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, Langlade-Demoyen P, Pivot X, Saas P, Maill\u00e8re B, Tartour E, Borg C, Adot\u00e9vi O (2012) Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res 18:2943\u20132953","journal-title":"Clin Cancer Res"},{"key":"2389_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nm.3442","volume":"20","author":"S Afshar-Sterle","year":"2014","unstructured":"Afshar-Sterle S, Zotos D, Bernard NJ, Scherger AK, R\u00f6dling L, Alsop AE, Walker J, Masson F, Belz GT, Corcoran LM, O\u2019Reilly LA, Strasser A, Smyth MJ, Johnstone R, Tarlinton DM, Nutt SL, Kallies A (2014) Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat Med 20:283\u2013290","journal-title":"Nat Med"},{"key":"2389_CR32","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/blood.V99.10.3748","volume":"99","author":"WK Roberts","year":"2002","unstructured":"Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA (2002) Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood 99:3748\u20133755","journal-title":"Blood"},{"key":"2389_CR33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrc2373","volume":"8","author":"CJ Melief","year":"2008","unstructured":"Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8:351\u2013360","journal-title":"Nat Rev Cancer"},{"key":"2389_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1475-2867-13-58","volume":"13","author":"H Ding","year":"2013","unstructured":"Ding H, Jin X, Ding N, Fu Z, Song Y, Zhu J (2013) Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma. Cancer Cell Int 13:58","journal-title":"Cancer Cell Int"},{"key":"2389_CR35","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.leukres.2008.10.013","volume":"33","author":"A Sar","year":"2009","unstructured":"Sar A, Perizzolo M, Stewart D, Mansoor A, Difrancesco LM, Demetrick DJ (2009) Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. Leuk Res 33:792\u2013797","journal-title":"Leuk Res"},{"key":"2389_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3324\/haematol.2008.001024","volume":"94","author":"NA Johnson","year":"2009","unstructured":"Johnson NA, Leach S, Woolcock B, deLeeuw RJ, Bashashati A, Sehn LH, Connors JM, Chhanabhai M, Brooks-Wilson A, Gascoyne RD (2009) CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 94:423\u2013427","journal-title":"Haematologica"},{"key":"2389_CR37","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1158\/1078-0432.CCR-08-1403","volume":"15","author":"Y Terui","year":"2009","unstructured":"Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K (2009) Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin\u2019s lymphoma. Clin Cancer Res 15:2523\u20132530","journal-title":"Clin Cancer Res"},{"key":"2389_CR38","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2009-06-229112","volume":"115","author":"C Henry","year":"2010","unstructured":"Henry C, Deschamps M, Rohrlich PS, Pallandre JR, R\u00e9my-Martin JP, Callanan M, Traverse-Glehen A, GrandCl\u00e9ment C, Garnache-Ottou F, Gressin R, Deconinck E, Salles G, Robinet E, Tiberghien P, Borg C, Ferrand C (2010) Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. Blood 115:2420\u20132429","journal-title":"Blood"},{"key":"2389_CR39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ijc.29366","volume":"137","author":"C Vauchy","year":"2015","unstructured":"Vauchy C, Gamonet C, Ferrand C, Daguindau E, Galaine J, Beziaud L, Chauchet A, Henry Dunand CJ, Deschamps M, Rohrlich PS, Borg C, Adotevi O, Godet Y (2015) CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes. Int J Cancer 137:116\u2013126","journal-title":"Int J Cancer"},{"key":"2389_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40164-016-0036-3","volume":"5","author":"C Gamonet","year":"2016","unstructured":"Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C (2016) New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Exp Hematol Oncol 5:7","journal-title":"Exp Hematol Oncol"},{"key":"2389_CR41","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2337\/db09-1486","volume":"59","author":"JH Velthuis","year":"2010","unstructured":"Velthuis JH, Unger WW, Abreu JR, Duinkerken G, Franken K, Peakman M, Bakker AH, Reker-Hadrup S, Keymeulen B, Drijfhout JW, Schumacher TN, Roep BO (2010) Simultaneous detection of circulating autoreactive CD8\u2009+\u2009T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 59:1721\u20131730","journal-title":"Diabetes"},{"key":"2389_CR42","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1182\/blood-2010-04-280875","volume":"116","author":"S Delluc","year":"2010","unstructured":"Delluc S, Ravot G, Maillere B (2010) Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 116:4542\u20134545","journal-title":"Blood"},{"key":"2389_CR43","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.immuni.2015.05.001","volume":"42","author":"W Yu","year":"2015","unstructured":"Yu W, Jiang N, Ebert PJ, Kidd BA, M\u00fcller S, Lund PJ, Juang J, Adachi K, Tse T, Birnbaum ME, Newell EW, Wilson DM, Grotenbreg GM, Valitutti S, Quake SR, Davis MM (2015) Clonal deletion prunes but does not eliminate self-specific \u03b1\u03b2 CD8(+) T lymphocytes. Immunity 42:929\u2013941","journal-title":"Immunity"},{"key":"2389_CR44","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.4049\/jimmunol.1402548","volume":"195","author":"C Chevaleyre","year":"2015","unstructured":"Chevaleyre C, Benhamouda N, Favry E, Fabre E, Mhoumadi A, Nozach H, Marcon E, Cosler G, Vinatier E, Oudard S, Hans S, Le Pimpec-Barthes F, Bats AS, Castelli FA, Tartour E, Maill\u00e8re B (2015) The tumor antigen cyclin B1 hosts multiple CD4 T cell epitopes differently recognized by pre-existing naive and memory cells in both healthy and cancer donors. J Immunol 195:1891\u20131901","journal-title":"J Immunol"},{"key":"2389_CR45","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.4049\/jimmunol.0900008","volume":"182","author":"Y Liu","year":"2009","unstructured":"Liu Y, Peng Y, Mi M, Guevara-Patino J, Munn DH, Fu N, He Y (2009) Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J Immunol 182:5960\u20135969","journal-title":"J Immunol"},{"key":"2389_CR46","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/eji.201041235","volume":"41","author":"SR Sierro","year":"2011","unstructured":"Sierro SR, Donda A, Perret R, Guillaume P, Yagita H, Levy F, Romero P (2011) Combination of lentivector immunization and low-dose chemotherapy or PD-1\/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 41:2217\u20132228","journal-title":"Eur J Immunol"},{"key":"2389_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/10849780152389384","volume":"16","author":"AA Noujaim","year":"2001","unstructured":"Noujaim AA, Schultes BC, Baum RP, Madiyalakan R (2001) Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13\u2013evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 16:187\u2013203","journal-title":"Cancer Biother Radiopharm"},{"key":"2389_CR48","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/annonc\/mdh472","volume":"15","author":"JS de Bono","year":"2004","unstructured":"de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW (2004) Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol 15:1825\u20131833","journal-title":"Ann Oncol"},{"key":"2389_CR49","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1158\/1078-0432.CCR-07-0507","volume":"13","author":"C Taylor","year":"2007","unstructured":"Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R (2007) Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 13:5133\u20135143","journal-title":"Clin Cancer Res"},{"key":"2389_CR50","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1158\/1078-0432.CCR-12-2426","volume":"19","author":"RM Srivastava","year":"2013","unstructured":"Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, L\u00f3pez-Albaitero A, Gibson SP, Gooding WE, Ferrone S, Ferris RL (2013) Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 19:1858\u20131872","journal-title":"Clin Cancer Res"},{"key":"2389_CR51","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3389\/fimmu.2017.00950","volume":"8","author":"C Deligne","year":"2017","unstructured":"Deligne C, Milcent B, Josseaume N, Teillaud JL, Sib\u00e9ril S (2017) Impact of depleting therapeutic monoclonal antibodies on the host adaptive immunity: a bonus or a malus? Front Immunol 8:950","journal-title":"Front Immunol"},{"key":"2389_CR52","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1084\/jem.20090504","volume":"206","author":"R Geiger","year":"2009","unstructured":"Geiger R, Duhen T, Lanzavecchia A, Sallusto F (2009) Human naive and memory CD4\u2009+\u2009T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med 206:1525\u20131534","journal-title":"J Exp Med"},{"key":"2389_CR53","doi-asserted-by":"publisher","first-page":"285ra63","DOI":"10.1126\/scitranslmed.aaa2546","volume":"7","author":"PJ Hanley","year":"2015","unstructured":"Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop HE, Rooney CM, Shpall EJ, Barrett AJ, Rodgers JR, Bollard CM (2015) CMV-specific T cells generated from na\u00efve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med 7:285ra63","journal-title":"Sci Transl Med"},{"key":"2389_CR54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.coi.2017.07.004","volume":"47","author":"M Melssen","year":"2017","unstructured":"Melssen M, Slingluff CL Jr (2017) Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol 47:85\u201392","journal-title":"Curr Opin Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02389-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02389-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02389-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:07:09Z","timestamp":1695168429000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02389-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,7]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2389"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02389-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,7]]},"assertion":[{"value":"3 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This non-interventional study, which complies with the Declaration of Helsinki, was approved by the appropriate regional ethics committee (\u201cComit\u00e9s de Protection des Personnes\u201d, Ile-de-France, France) regulated by the government institution \u201cAgence R\u00e9gionale de Sant\u00e9\u201d (ARS, Bobigny, France), by the government advisory board for data processing in health care (\u201cComit\u00e9 Consultatif sur le Traitement de l\u2019Information en mati\u00e8re de Recherche dans le Domaine de la Sant\u00e9\u201d, Paris, France) (CCTIRS N\u00b014.626), and by the French data protection authority (\u201cCommission Nationale de l\u2019Informatique et des Libert\u00e9s\u2009\u00bb\u2009, Paris, France) (CNIL N\u00b0DR-2015-237). PBMCs from HD were obtained from CTL\u2014Europe or from the EFS. Spleens were obtained from organ transplant donors at the H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (Paris, France), in accordance with national ethics guidelines governing the use of human tissues (Scientific collecting authorization, government institution \u201cAgence de la biom\u00e9decine\u201d, Saint Denis, France) (N\u00b0PFS14-009). All animal studies were performed in compliance with guidelines from the European Union (EU guideline on animal experiments, European Directive #2010\/63\/EU) and the national charter on ethics in animal experiments and were approved by the local Charles Darwin Ethics Committee in Animal Experiments, Paris, France (Authorization Number 01530.02).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"All FL patients provided informed written consent to participate in this research study (CCTIRS N\u00b014.626 and CNIL N\u00b0DR-2015-237). Written informed consents were obtained by the French state agency EFS () for the use of blood of anonymous healthy donors for research purposes. Human PBMCs from CTL-Europe were collected from sources that have confirmed that they were obtained from healthy donors with informed consent in accordance with applicable laws. Spleens were collected from organ transplant donors at the H\u00f4pital Piti\u00e9-Salp\u00e9tri\u00e8re (Paris, France) (written protocol N\u00b0PFS14-009, Agence de la biom\u00e9decine), following national ethical guidelines (L1232-1, L1232-3;) regulating the use of human tissues for research purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"HLA-A2.1-\/HLA-DR1-transgenic H-2 class I-\/class II-KO female C57Bl\/6 mice were developed by Dr. Lone\u00a0at Institut Pasteur\u2014Paris in Dr. F. Lemonnier laboratory. HLA\u2010A2.1 transgenic H\u20102 class I\u2010KO (\u03b22\u00a0m<sup>0<\/sup>)\u00a0(obtained at Institut Pasteur\u2014Paris in Dr. F. Lemonnier laboratory) and HLA\u2010DR1 transgenic H\u20102 class II\u2010KO (IA\u03b2<sup>b\u00b0<\/sup>) (obtained at Institut Pasteur\u2014Lille from Dr. C. Auriault)\u00a0mice were intercrossed and progenies screened until HLA\u2010A2.1<sup>+\/+<\/sup>\/HLA\u2010DR1<sup>+\/+<\/sup> double\u2010transgenic H\u20102 class I-\/class II-KO animals were obtained []. All mice were maintained in pathogen-free facilities.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal source"}},{"value":"C57BL\/6 mice-derived EL4 thymoma cells expressing human CD20 (EL4-huCD20) were kindly provided by Pr. Jos\u00e9e Golay from the Center of Cellular Therapy \u201cG. Lanzani\u201d, USC Haematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy. EL4 cells obtained from the American-Type Culture Collection (ATCC, Manassas, VA) were infected with the Moloney-derived long terminal repeat (LTR)-CD20-LTR vector containing the human CD20 cDNA []. The expression of human CD20 on EL4-huCD20 cells was validated before each experiment by flow cytometry using a mouse anti-human CD20 mAb (2H7, BD Biosciences). HLA-DRB1*01:01-expressing AAPCs derived from murine fibroblasts NIH-3T3 cells were developed by Dr. Toutirais and Dr. Latouche. NIH-3T3 cells (obtained from ATCC) were transduced with the common HLA-DR\u03b1 chain, the specific HLA-DR\u03b21*01:01 chain, and with the co-stimulatory and adhesion human molecules B7.1, ICAM-1 and LFA-3 []. Phenotypic expression of transduced molecules on AAPCs was validated by flow cytometry using anti\u2010human LFA\u20103, B7.1, ICAM\u20101 mAbs (BD Biosciences) and an anti\u2010HLA\u2010DR complex mAb (Santa Cruz Biotechnology).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentification"}}]}}